Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia

Autor:	William W.L. Choi, Cheuk Him Man, Howard C.H. Chow, Harinder Gill, Alvin H. W. Ip, Yok-Lam Kwong, Anskar Y.H. Leung
Jazyk:	angličtina
Rok vydání:	2015
Předmět:	Sorafenib Niacinamide Myeloid Azacitidine Gene Expression Antineoplastic Agents Apoptosis Biology Pharmacology Drug Administration Schedule Monocytes chemistry.chemical_compound Mice fluids and secretions hemic and lymphatic diseases Cell Line Tumor medicine Animals Humans Midostaurin Online Only Articles Protein Kinase Inhibitors Quizartinib Phenylurea Compounds Remission Induction Myeloid leukemia hemic and immune systems Drug Synergism Hematology medicine.disease Survival Analysis Xenograft Model Antitumor Assays Leukemia Leukemia Myeloid Acute medicine.anatomical_structure Treatment Outcome chemistry fms-Like Tyrosine Kinase 3 embryonic structures Fms-Like Tyrosine Kinase 3 Mutation Cancer research medicine.drug
Popis:	Internal tandem duplication (ITD) of the fms-like tyrosine kinase 3 ( FLT3 ) gene in acute myeloid leukemia (AML) confers an inferior prognosis.[1][1],[2][2] Multi-kinase inhibitors against FLT3 , including midostaurin, sorafenib and quizartinib, have been evaluated either as single agents or in
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18557f42482aa52bb2091bc376a64eb1 https://europepmc.org/articles/PMC4486234/ Zobrazit plný text záznamu